4Q FY26 Quarterly Activity Report and Appendix 4C
Filed with ASX · · 8 pages · English
Summary by 6ix AI
The report indicates a decline in revenue and profit compared to the previous corresponding period, attributed to challenges in the pharmaceutical budget cycle. Despite these challenges, the company achieved cash flow break-even and reported a net cash position at the end of the period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Adheris Health's latest callMedAdvisor Limited (MDR) Q1 2026 Earnings Call · Replay · Oct 21, 2025Read the transcript of MedAdvisor Limited (MDR) Q1 2026 Earnings CallStory so far
Earlier from Adheris Health
- Q3 FY26 Results Presentation
- 3Q FY26 Quarterly Activity Report and Appendix 4C
- FY26 Half Year Results
- Appendix 4D & FY26 Half Year Report
- Non-Deal Roadshow Presentation & Operating Cost Update
Later from Adheris Health
All Adheris Health news releasesFollow Adheris Health into a list and get an email when it puts out news.
Follow Adheris Health